Arexera Therapeutics plans to launch a Phase 1 trial testing its experimental treatment ATL-101 in Huntington's patients ...

For Jill, the issue isn’t whether life has value. It is what kind of life is being preserved. If she can no longer eat without choking, recognize loved ones, or share what she wants, would inserting a ...

One thing that helps columnist Tanita Allen ease fear about future symptoms is separating what she can do today from what she ...

Columnist Tanita Allen's mindfulness and meditation practice has taught her that she doesn't need to fight herself every ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google My wife, Jill, who is gene-positive with Huntington’s disease (HD ...

Differences in brain connections for people who carry a mutation known to cause Huntington’s disease are detectable decades before the onset of motor symptoms, a study showed. The findings suggested ...

Two types of orally available small molecules ameliorated symptoms and slowed progression of Huntington’s disease in a mouse model, a study reported. The treatments effectively reduced the levels of ...

Several late-stage clinical trials are now recruiting participants to test whether three experimental oral therapies can slow the progression of Huntington’s disease, with active or planned sites in ...

Research is currently ongoing to find a cure for Huntington’s disease and to develop new therapies that might be able to prevent or delay disease progression and better manage the symptoms of the ...

Atalanta Therapeutics has raised $97 million to support planned Phase 1 clinical trials of its experimental RNA interference (RNAi)-based therapies for Huntington’s disease and a genetic form of ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Huntington’s disease doesn’t give you a map. There is no ...

A global clinical trial testing SKY-0515, Skyhawk Therapeutics’ daily oral therapy for Huntington’s disease, will soon start recruiting adults with the genetic condition in the U.S., Canada, and the U ...